r/10xPennyStocks

I wanted to separate the **facts from the speculation** coming out of the latest earnings call, for Elite Pharmaceutical (ELTP), then provide my updated valuation.

**1. Current Business — Facts**

ELTP reported Q1 FY2027 revenue of **$32.4M**, operating income of **$7.5M**, operating cash flow of **$10.1M**, and cash of **$38.9M**, up from $29.8M at the beginning of the fiscal year.

Management described the business as stable over the past four quarters. The year-over-year revenue decline is largely attributable to the normalization of generic Vyvanse pricing. The June 2025 quarter benefited from unusually high prices when ELTP launched Lisdex with limited competition. Competition subsequently increased and pricing reached equilibrium.
Importantly, the underlying volume trends remain positive:

**Overall volume: +14.75%**
**Lisdex volume: +10%**
**Lisdex market share: +10.2%**

Management also said market share increased across its four major products.
So while revenue is lower year-over-year, the underlying business does **not appear to be in fundamental decline**. Volumes and market share are increasing while pricing has normalized.

**2. Pipeline — Facts**

The pipeline continues to produce tangible milestones. Methadone launched in April and Ropinirole ER launched in July. These are smaller opportunities, but they add incremental revenue.
ELTP also completed a successful BE study for an undisclosed anticonvulsant with approximately **$840M in annual branded sales**, according to management, and is preparing the ANDA.

ELTP filed an ANDA for an undisclosed anticoagulant associated with approximately **$26B in annual sales**. Management is negotiating patent issues and believes a **2028 launch may be possible**, although that remains speculative.

Oxy ER remains under FDA review with an unresolved anti-abuse testing issue, so the previously discussed August 2027 launch should **not** be viewed as guaranteed.

**3. M&A — Facts vs. Speculation**

ELTP has apparently been pursuing M&A for approximately a year without announcing a transaction.

Management has now extended its M&A firm’s engagement for another **six months**. Nasrat said the extension is intended to allow them to **“finalize a couple of things.”**

At the same time, management said NASDAQ is moving forward regardless of whether an acquisition occurs.

**What could the six-month extension mean?**
This is speculation, but it is one of the more interesting parts of the call. After roughly a year, ELTP could have simply ended the engagement if there were no viable opportunities. Instead, management chose to extend it.

Possibilities include an interested buyer remaining involved, ongoing due diligence, valuation or structural negotiations, or a potential buyer waiting for additional milestones such as the anticonvulsant ANDA.

**None of this confirms that a transaction is coming.**

Another possibility is that NASDAQ is giving ELTP greater negotiating leverage. The company has approximately **$39M in cash, $32M in quarterly revenue, $7.5M in quarterly operating income and growing market share.** ELTP doesn’t need an acquisition simply to continue operating.
That potentially allows management to reject an offer it believes undervalues the company.

**4. NASDAQ**

Nasrat was unusually direct:
**“Regardless of what happens, we’re going to be at NASDAQ.”**

He said ELTP could uplist independently, after acquiring another company, or as part of an acquisition. His stated expectation was that by the **February 2027 call**, NASDAQ would either have occurred or be close to completion.
NASDAQ does not automatically create value, but it could potentially provide greater liquidity, broader investor access, institutional visibility and a higher valuation multiple.

It could also strengthen M&A by giving ELTP greater visibility and a publicly established market valuation.

**5. Biggest Risks**

The biggest risk is **pipeline execution**. The $840M anticonvulsant and $26B anticoagulant figures represent the size of the underlying markets—not ELTP’s future revenue. Actual value depends on FDA approval, patents, launch timing, competition, pricing and market share.
Oxy ER also has a meaningful FDA issue that must be resolved. And, despite the M&A extension, **there is no confirmed acquisition.**
One additional point worth verifying: I have seen the argument that ELTP has historically received FDA approval for every ANDA it has filed. If that is accurate, it would be an interesting part of the company’s historical record, but I would personally verify the complete filing/approval history before presenting that as a fact.

**6. My Conservative Valuation**

Having said all that, here are my updated valuations.

**I intentionally use conservative numbers.** I’m sure many people will think they’re far too low, and I’m completely comfortable with that. I prefer to build the investment case around worst-case or highly conservative assumptions. If the actual outcome is better, that simply creates more upside than I anticipated.

**What is ELTP worth today based ONLY on the existing business?**

**Approximately $0.38–$0.45 IF we assigned virtually no value to the future pipeline, M&A or NASDAQ** and focus on the existing profitable business, cash generation and balance sheet.

At the current **$0.31**, I believe the stock is modestly undervalued based on the existing business, assuming current earnings remain sustainable.

**So…..if nothing meaningful happens…and ZERO products come to fruition and ZERO growth with currents products….**

**Approximately $0.38-$0.45**
This assumes the core business remains around current levels, but there is no meaningful pipeline contribution, M&A, NASDAQ catalyst or major new product growth.

**If some things go right? Approximately $0.55–$0.75**

This would involve continued stability/growth in the core business, NASDAQ progress, the anticonvulsant ANDA, additional BE/ANDA catalysts and contributions from newer products.
At $0.31, that’s approximately **77%–142% upside.**

This is the range I consider the **most realistic 6–12 month bullish scenario**.

**If lots of things go right? Approximately $0.85–$1.15**

This would require meaningful progress across several areas: NASDAQ, the anticonvulsant, anticoagulant, Oxy ER and continued growth in the existing business.
At $0.31, that’s approximately **175%–270% upside.**

**If M&A or a major pipeline opportunity materializes? $1.25–$1.75+**

This is the high-end scenario and should **not** be included in today’s fundamental valuation.
It’s potential upside if a legitimate acquisition or major pipeline development materially changes ELTP’s future earnings power.

**7. My Simple Take**

**Today:** \~$0.40

**In 6 months:**

**With moderate success:** \~$0.65

**Strong execution:** \~$1.00–$1.15

**M&A/major pipeline success:** $1.25+

At **$0.31**, I believe the market is primarily valuing ELTP on its existing business and assigning **relatively little value to the pipeline, NASDAQ and M&A possibilities.**

The existing business provides the foundation. The pipeline and strategic catalysts provide the potential upside.

The biggest thing ELTP needs now is evidence of the next leg of growth. The most important catalysts are the anticonvulsant ANDA, NASDAQ, additional BE results, Oxy ER, the anticoagulant opportunity and M&A.

**Bottom line:**

At $0.31, I see an interesting risk/reward setup: the existing profitable business provides fundamental support, while successful execution of several upcoming catalysts could potentially produce 2–4× upside.

That’s ultimately what makes ELTP interesting to me—not that everything will go right, but that the current price doesn’t appear to require everything to go right to generate a meaningful return.

Not investment advice. Do your own research.

Disclaimer: I’m long ELTP. I’ve been here 15+ years and have never sold a single share.

Sunday morning’s always the calm before the storm, and with small caps making some big moves in the last few trading days, I’m curious to know what’s on others’ watchlists - and why!

Drop your rationale for what you’re watching for: breakout, news, volume, reversal, etc.

Our community at Trading Desk loves these deep dives as well. Feel free to join the fun and share your ideas at our Trading Desk discord: https://discord.com/invite/bNXUyGe5KS

I still see real value in ELTP after today’s results, but I would lower the near-term valuation from what I would have assigned before seeing this quarter. The company generated $32.4M of revenue and $7.5M of operating income, while the 65% year-over-year operating-income decline was primarily attributable to lower Vyvanse margins rather than a collapse in the underlying business. Cash also remains around $29M, after ending FY2026 at $29.8M, when the company generated $49.1M of operating income for the full year. The key positive is that ELTP still has substantial earnings power, with a potentially significant pipeline that isn’t reflected in today’s quarter. Based strictly on today’s financial results—not assigning much value yet to the future ANDAs or a potential buyout—I would put a reasonable current value around $0.60–$0.75 per share, with ~$0.70 being my fair-value midpoint. If tomorrow’s call confirms that the Vyvanse margin pressure is temporary and management maintains a strong FY2027 growth outlook, I could justify $0.80–$1.00+. Conversely, if management indicates that the lower margins are the new normal, I’d move toward $0.45–$0.60. In other words, I don’t think today’s earnings break the ELTP investment thesis; they do, however, make $1+ dependent on future growth rather than the current earnings run rate.

My personal risk/reward assessment after today’s filing: I would put $0.70 as the reasonable current value, ~$0.40 as the downside case, and $1.10–$1.30 as the upside case. The key swing factor is tomorrow’s call. If management says the Vyvanse margin compression is temporary and gives confidence in continued growth, I’d move my valuation toward $1+. If they indicate the lower margins are permanent, I’d move it toward $0.40–$0.50. Today’s results themselves don’t justify a $1+ valuation yet, but they also don’t justify treating ELTP as a broken company: it still produced $7.5M operating income and $5.9M net income in the quarter, and management says the quarter was in line with the preceding three quarters.

A factual way to frame it is: ELTP is trading at roughly $0.36 today, yet the stock is now below where it traded around the November 2024 FDA approval of generic Vyvanse. Since that approval, the company has gone on to produce record FY2026 revenue of approximately $149M and $49.1M of operating income, with revenue up 77% year over year. Despite that dramatic improvement in the underlying business, the stock remains roughly 50% below the ~$0.70+ levels it traded around the Vyvanse approval period. Today’s results also show that ELTP remains profitable, generating $32.4M of revenue, $7.5M of operating income and $5.9M of net income in Q1 FY2027, although Vyvanse margin compression significantly reduced profitability. So the central valuation question isn’t whether ELTP has grown—it clearly has; it’s why the market is valuing the company at substantially less today despite that growth.

What are our thoughts on $HTZ today? Buy or sell?

Chicken feet guy here.

I gave you $WYHG at $3.50 which 6 bagged today. (Check my post history if you wish).

For those that missed it, I now bring you the next explosive low cap stock.

$WLDS. AKA dollar store apple watch rip off. THE COMPANY IS GARBAGE! But this one is looking set for an explosive move. Technicals are all lined up.

The borrow: 949.34% fee. Zero available at IBKR. 731% → 932% → 949% in four days, hitting zero repeatedly. That’s roughly 2.6% a day just to stay short.

Reg SHO: On the Nasdaq threshold list, 4 August file. Don’t take my word for it. the file is public, go pull it.

The float: 2,189,469 shares outstanding as of the 17 June 13D.

Oh and activist investors trying to do a hostile takeover have bought 25% of the company, and they’ve asked the board to not conduct any dilutive raises whilst they attempt to sort things out. Court ordered.

Do not miss out this time. Chicken feet, Apple Watch guy out.

🐔🐣⌚️🍎

Big Digital Energy Announces Strategic Tensor IQ LOI to Advance Hood County, Texas AI Infrastructure Campus
Agreement marks critical step towards development of 17 MW of AI/HPC capacity
Agreement expected to generate $546 million in revenues to TLH over initial 15-year contract with potential to reach over $1 billion if extended to 25 years

I don’t think so. I’ve been looking through names like $NXE, $DNN, $UEC, and $UUUU,$CCJ  but I’m still trying to understand the differences between their projects, timelines, and risks.

Some people think the uranium story is just getting started, while others believe a lot of the upside is already priced in.

Where do you think we are in the cycle still early, somewhere in the middle, or already late?